84 related articles for article (PubMed ID: 17578348)
1. Hypermethylation of the COX-2 gene is a potential prognostic marker for cervical cancer.
Jo H; Kang S; Kim JW; Kang GH; Park NH; Song YS; Park SY; Kang SB; Lee HP
J Obstet Gynaecol Res; 2007 Jun; 33(3):236-41. PubMed ID: 17578348
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer.
Kang S; Kim JW; Kang GH; Park NH; Song YS; Kang SB; Lee HP
Gynecol Oncol; 2005 Jan; 96(1):173-80. PubMed ID: 15589597
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
5. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer.
Hsu HS; Wen CK; Tang YA; Lin RK; Li WY; Hsu WH; Wang YC
Clin Cancer Res; 2005 Aug; 11(15):5410-6. PubMed ID: 16061855
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer.
de Maat MF; van de Velde CJ; Umetani N; de Heer P; Putter H; van Hoesel AQ; Meijer GA; van Grieken NC; Kuppen PJ; Bilchik AJ; Tollenaar RA; Hoon DS
J Clin Oncol; 2007 Nov; 25(31):4887-94. PubMed ID: 17971584
[TBL] [Abstract][Full Text] [Related]
8. Prognostic DNA methylation marker in serum of cancer patients.
Müller HM; Fiegl H; Widschwendter A; Widschwendter M
Ann N Y Acad Sci; 2004 Jun; 1022():44-9. PubMed ID: 15251938
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation of the p16 gene is associated with poor prognosis in recurrent early-stage hepatocellular carcinoma.
Ko E; Kim Y; Kim SJ; Joh JW; Song S; Park CK; Park J; Kim DH
Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2260-7. PubMed ID: 18723830
[TBL] [Abstract][Full Text] [Related]
10. CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer.
Ellinger J; Albers P; Perabo FG; Müller SC; von Ruecker A; Bastian PJ
J Urol; 2009 Jul; 182(1):324-9. PubMed ID: 19447423
[TBL] [Abstract][Full Text] [Related]
11. Biological significance of promoter hypermethylation of tumor-related genes in patients with gastric carcinoma.
Ksiaa F; Ziadi S; Amara K; Korbi S; Trimeche M
Clin Chim Acta; 2009 Jun; 404(2):128-33. PubMed ID: 19336228
[TBL] [Abstract][Full Text] [Related]
12. Methylation of serum DNA is an independent prognostic marker in colorectal cancer.
Wallner M; Herbst A; Behrens A; Crispin A; Stieber P; Göke B; Lamerz R; Kolligs FT
Clin Cancer Res; 2006 Dec; 12(24):7347-52. PubMed ID: 17189406
[TBL] [Abstract][Full Text] [Related]
13. Reprimo as a potential biomarker for early detection in gastric cancer.
Bernal C; Aguayo F; Villarroel C; Vargas M; Díaz I; Ossandon FJ; Santibáñez E; Palma M; Aravena E; Barrientos C; Corvalan AH
Clin Cancer Res; 2008 Oct; 14(19):6264-9. PubMed ID: 18829507
[TBL] [Abstract][Full Text] [Related]
14. Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer.
Choi CH; Lee KM; Choi JJ; Kim TJ; Kim WY; Lee JW; Lee SJ; Lee JH; Bae DS; Kim BG
Cancer Lett; 2007 Sep; 255(1):26-33. PubMed ID: 17467893
[TBL] [Abstract][Full Text] [Related]
15. A gene hypermethylation profile of human cancer.
Esteller M; Corn PG; Baylin SB; Herman JG
Cancer Res; 2001 Apr; 61(8):3225-9. PubMed ID: 11309270
[TBL] [Abstract][Full Text] [Related]
16. Detecting cervical cancer by quantitative promoter hypermethylation assay on cervical scrapings: a feasibility study.
Reesink-Peters N; Wisman GB; Jéronimo C; Tokumaru CY; Cohen Y; Dong SM; Klip HG; Buikema HJ; Suurmeijer AJ; Hollema H; Boezen HM; Sidransky D; van der Zee AG
Mol Cancer Res; 2004 May; 2(5):289-95. PubMed ID: 15192122
[TBL] [Abstract][Full Text] [Related]
17. Promoter methylation of death-associated protein kinase and its role in irradiation response in cervical cancer.
Leung RC; Liu SS; Chan KY; Tam KF; Chan KL; Wong LC; Ngan HY
Oncol Rep; 2008 May; 19(5):1339-45. PubMed ID: 18425396
[TBL] [Abstract][Full Text] [Related]
18. Comparison of DNA hypermethylation patterns in different types of uterine cancer: cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma.
Kang S; Kim JW; Kang GH; Lee S; Park NH; Song YS; Park SY; Kang SB; Lee HP
Int J Cancer; 2006 May; 118(9):2168-71. PubMed ID: 16331610
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
Jarmalaite S; Jankevicius F; Kurgonaite K; Suziedelis K; Mutanen P; Husgafvel-Pursiainen K
Oncology; 2008; 75(3-4):145-51. PubMed ID: 18824877
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma.
Jung YW; Kim SW; Kim S; Kim JH; Cho NH; Kim JW; Kim YT
Eur J Obstet Gynecol Reprod Biol; 2010 Jan; 148(1):62-6. PubMed ID: 19836124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
